In short
A new clinical trial is investigating the potential of Tilsotolimod Sodium (IMO-2125) in treating advanced melanoma. This study focuses on patients with pT3-4 cN0M0 melanoma, examining how intradermal administration of the drug might affect tumor presence in sentinel lymph nodes and impact overall patient outcomes.
At a glance
- Drug Name
- Tilsotolimod Sodium (IMO-2125)
- Trial Phase
- Phase II
- Condition
- pT3-4 cN0M0 Melanoma
- Administration
- Intradermal injection
- Dosage
- 8 mg maximum daily dose
- Primary Endpoint
- Rate of tumor-positive sentinel lymph nodes seven days after treatment
- Secondary Endpoints
- Immune cell responses, Recurrence-Free Survival, Overall Survival
- Follow-up Duration
- Up to 10 years after sentinel node biopsy
What is Tilsotolimod Sodium?
Tilsotolimod Sodium, also known as IMO-2125, is an investigational drug being studied for the treatment of advanced melanoma. It is a type of medication called a nucleic acid, which means it's made up of the same building blocks as our DNA. This drug is currently being tested to see if it can help patients with a specific type of advanced skin cancer.
Medical Condition: Advanced Melanoma
The specific condition being targeted in this study is pT3-4 cN0M0 Melanoma. Let's break down what this means: Melanoma: This is a type of skin cancer that develops in the cells that produce melanin, the pigment that gives skin its color. pT3-4: This refers to the thickness of the tumor. T3 and T4 tumors are considered thick, which often indicates a more advanced stage of melanoma. cN0: This means that there are no detectable cancer cells in the nearby lymph nodes. M0: This indicates that the cancer has not spread to distant parts of the body.
How Tilsotolimod Sodium Works
Tilsotolimod Sodium is designed to stimulate the body's immune system to fight against cancer cells. It works by: Increasing the number and activation of certain immune cells called dendritic cells in the lymph nodes and blood. Enhancing the activity of T cells that can recognize and attack melanoma cells. By boosting these aspects of the immune system, the drug aims to improve the body's natural ability to fight the cancer.
Current Clinical Trial
A clinical trial called the "Intrim 1 study" is currently underway to test the effectiveness of Tilsotolimod Sodium. This is a Phase II trial, which means it's designed to gather more information about the drug's effectiveness and safety. The main goal of this trial is to see if Tilsotolimod Sodium can reduce the number of patients who have cancer cells in their sentinel lymph nodes (SLN). The sentinel lymph node is the first lymph node where cancer cells are likely to spread from the primary tumor.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Some key eligibility requirements include: Being 18 years of age or older Having a confirmed diagnosis of primary malignant melanoma with a tumor depth greater than 2.0 mm Having a good overall health status (WHO Performance Status ≤1) There are also several conditions that would exclude a person from participating, such as having active autoimmune disease or other types of cancer.
Administration and Dosage
Tilsotolimod Sodium is administered as a solution for injection. In this trial, it's given through an intradermal injection, which means it's injected directly into the skin. The maximum daily dose being tested is 8 mg. The treatment is given locally, near the site of the melanoma, with the aim of affecting the nearby lymph nodes.
Potential Benefits
While the full benefits of Tilsotolimod Sodium are still being studied, researchers hope to see several positive outcomes: Reduced presence of cancer cells in sentinel lymph nodes Improved immune response against melanoma cells Better recurrence-free survival (RFS) and overall survival (OS) rates for patients with advanced melanoma The trial will be monitoring these outcomes for up to 10 years after treatment to understand the long-term effects of the drug.